NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 109 filers reported holding NURIX THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,017,882 | -27.5% | 3,564,616 | -7.9% | 0.18% | -24.4% |
| Q2 2023 | $38,659,052 | +37.2% | 3,869,775 | +21.9% | 0.23% | +33.7% |
| Q1 2023 | $28,185,138 | +1.1% | 3,174,002 | +25.0% | 0.18% | -6.9% |
| Q4 2022 | $27,874,180 | -19.5% | 2,538,632 | -4.5% | 0.19% | -22.0% |
| Q3 2022 | $34,626,000 | +20.8% | 2,657,437 | +17.4% | 0.24% | +33.1% |
| Q2 2022 | $28,673,000 | +32.3% | 2,263,063 | +46.3% | 0.18% | +69.2% |
| Q1 2022 | $21,669,000 | -37.8% | 1,546,689 | +28.5% | 0.11% | -24.6% |
| Q4 2021 | $34,844,000 | -0.7% | 1,203,589 | +2.7% | 0.14% | -0.7% |
| Q3 2021 | $35,103,000 | +10.8% | 1,171,657 | -1.9% | 0.14% | +10.9% |
| Q2 2021 | $31,693,000 | -1.6% | 1,194,615 | +15.3% | 0.13% | -11.0% |
| Q1 2021 | $32,200,000 | – | 1,035,701 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |